Following early preclinical evidence, several phase 2 and 3 clinical trials have investigated the efficacy of triple combination with ICIs and BRAF/MEK inhibitors in patients with advanced BRAFV600-mutant melanoma. The gene discussed is MAP2K7; the disease is melanoma.